Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 48, Issue 3, pp 454–458 | Cite as

Concurrent presentation of a hemorrhagic pericardial effusion and venous thromboembolism in malignancy: a systematic review of case studies

  • Krishna Pabba
  • Cristhiam M. Rojas-HernandezEmail author
Article
  • 64 Downloads

Abstract

The concurrent presentation of symptomatic malignant pericardial hemorrhage and venous thromboembolism is a rare event that poses a clinical dilemma. Existing VTE guidelines do not indicate when, or if, anticoagulation therapy should be started after the treatment of the pericardial bleed. We performed a systematic review to compile the published clinical evidence on the occurrence of coexisting pericardial hemorrhage and VTE in cancer patients and to describe the clinical presentations and bleeding and thrombosis outcomes before and after anticoagulation therapy. We studied published case reports on patients with cancer who presented to the hospital with pericardial hemorrhage and VTE through April 11, 2019. We found seven published case reports. All patients had suffered from a pulmonary embolism and had pericardiocentesis during hospitalization. Five patients (71%) had lung cancer. Four patients (57%) were started on anticoagulation after pericardial drainage and survived the index event. Two patients (29%) were not started on anticoagulation after pericardiocentesis; only one of these patients survived the hospitalization. Pericardial bleeding risk in cancer may be inherent to malignancy, and it is unclear if anticoagulation use increases the risk of recurrent pericardial bleeding. The management of pericardial bleeding typically requires pericardiocentesis, and clinical registries, prospective collaboration projects, and case adjudication are needed to establish the safety of initiation of antithrombotic therapy in such patients.

Keywords

Malignancy Venous thromboembolism Pericardial effusion Pulmonary embolism Hemorrhage 

Notes

Author contributions

KP designed and performed the research and also wrote the manuscript. CMR-H also designed, performed the research, and revised the manuscript.

Compliance with ethical standards

Conflicts of interest

Dr. Rojas-Hernandez has received funding from Daichii-Sankyo clinical research with oral anticoagulants in cancer associated venous thrombosis. Dr Pabba has no competing interests to declare.

References

  1. 1.
    Wickham N, Gallus AS, Walters BN, Wilson A, Committee NVPGA (2012) Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Intern Med J 42(6):698–708.  https://doi.org/10.1111/j.1445-5994.2012.02808.x CrossRefGoogle Scholar
  2. 2.
    Belohlavek J, Dytrych V, Linhart A (2013) Pulmonary embolism, part I: epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 18(2):129–138Google Scholar
  3. 3.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632–634.  https://doi.org/10.1111/j.1538-7836.2007.02374.x CrossRefGoogle Scholar
  4. 4.
    Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Buller HR (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11(1):56–70.  https://doi.org/10.1111/jth.12070 CrossRefGoogle Scholar
  5. 5.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352CrossRefGoogle Scholar
  6. 6.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical P (2013) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(17):2189–2204.  https://doi.org/10.1200/jco.2013.49.1118 CrossRefGoogle Scholar
  7. 7.
    Mandala M, Falanga A, Roila F, Group EGW (2011) Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol 22:vi85–vi92.  https://doi.org/10.1093/annonc/mdr392 CrossRefGoogle Scholar
  8. 8.
    Lestuzzi C (2010) Neoplastic pericardial disease: old and current strategies for diagnosis and management. World J Cardiol 2(9):270–279.  https://doi.org/10.4330/wjc.v2.i9.270 CrossRefGoogle Scholar
  9. 9.
    Petrofsky M (2014) Management of malignant pericardial effusion. J Adv Pract Oncol 5(4):281–289Google Scholar
  10. 10.
    Thomas C, Lane K, Cecconi M (2014) Pulmonary embolism with haemorrhagic pericardial effusion and tamponade: a clinical dilemma. BMJ Case Rep.  https://doi.org/10.1136/bcr-2013-202285 Google Scholar
  11. 11.
    Jairath UC, Benotti JR, Spodick DH (2001) Cardiac tamponade masking pulmonary embolism. Clin Cardiol 24(6):485–486CrossRefGoogle Scholar
  12. 12.
    Akhbour S, Khennine BA, Oukerraj L, Zarzur J, Cherti M (2014) Pericardial tamponade and coexisting pulmonary embolism as first manifestation of non-advanced lung adenocarcinoma. Pan Afr Med J 18:15.  https://doi.org/10.11604/pamj.2014.18.15.2469 CrossRefGoogle Scholar
  13. 13.
    Hsi DH, Krishnamurthy M, Ryan GF, Luo P, Woodlock TJ (2010) Successful management of hemopericardium and cardiac tamponade secondary to occult malignancy and anticoagulation. Exp Clin Cardiol 15(2):e33–e35Google Scholar
  14. 14.
    Kandasamy S, Tadi MEF, Rudrapogu JS, Biju G, Boddikura C, Naralasetty AK (2017) Pericardial tamponade masking associated pulmonary thrombo embolism in a case of adeno carcinoma of lung. Int J Res Med Sci 3(8):2126–2128Google Scholar
  15. 15.
    Barski L, Shalev L, Zektser M, Malada-Mazri H, Abramov D, Rafaely Y (2012) Large hemorrhagic pericardial effusion. Israel Med Assoc J 14(6):367–371Google Scholar
  16. 16.
    Nguyen Ba V, Debien B, Villevieille T, Quiniou G, Pollet L, Lenoir B, Pats B (2003) Pulmonary embolism to the rescue in cardiac tamponade. Ann Fr Anesth Reanim 22(10):896–899CrossRefGoogle Scholar
  17. 17.
    Gornik HL, Gerhard-Herman M, Beckman JA (2005) Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 23(22):5211–5216.  https://doi.org/10.1200/JCO.2005.00.745 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineMcGovern Medical School at The University of Texas Health Science Center at HoustonHoustonUSA
  2. 2.Section of Benign HematologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations